Kit for detecting Neethton syndrome

By using specific primer pairs in the Netherton syndrome kit for PCR detection, the SPINK5 exon 26 rs2303070 (c.2475G>T) gene loci were used to solve the problems of diagnosis of misdiagnosis and complex gene detection in the prior art. It has achieved rapid and convenient diagnosis of Netherton syndrome and assessment of skin barrier function abnormalities, providing new research and development ideas for treatment and skin care products.

CN119220662APending Publication Date: 2024-12-31FIRST AFFILIATED HOSPITAL OF KUNMING MEDICAL UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411305905.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-19
Publication Date
2024-12-31

AI Technical Summary

Technical Problem

The prior art has misdiagnosis, invasive skin lesions and nonspecific pathological characteristics in the diagnosis of Netherton syndrome, and the genetic testing is complex, making it difficult to quickly clarify the diagnosis.

Method used

A kit for detecting Netherton syndrome including specific primer pairs is provided, and is specifically detected by PCR kit and peripheral blood detection using the SPINK5 exon 26 rs2303070 (c.2475G>T) gene loci.

Benefits of technology

A rapid, convenient and specific diagnosis of Netherton syndrome is achieved, new gene loci are provided for treatment in patients with impaired skin barriers, and simplified the diagnosis of skin diseases and the development of skin care products.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119220662A_ABST
    Figure CN119220662A_ABST
Patent Text Reader

Abstract

The invention relates to a kit for detecting Neethton syndrome, and belongs to the technical field of biomedicine. The kit comprises a forward primer and a reverse primer, the forward primer is 5 '-tgcaagacacatggcaata-3', and the reverse primer is 5 '-tgcaagacacacata-3'; the reverse primer is 5 '-gacagagtcagcatttcac-3', and the reverse primer is 5 '-gacagagtcagcatttcac-3'. The kit disclosed by the invention is convenient and quick to detect, has specificity, can be used for clearly diagnosing a patient suffering from the Neethton syndrome, can also be used for evaluating a patient suffering from barrier function abnormality of skin, and is easy to popularize and apply.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of biomedicine, and in particular relates to a kit for detecting Netherton syndrome. Background Art

[0002] Netherton syndrome (NS) is a rare autosomal recessive disease caused by mutations in the serine protease inhibitor Kazal type 5 (SPINK5), with an incidence of approximately 1 / 200,000, which mainly affects the skin, hair, and immune system. Mutations in SPINK5 lead to the loss of lymphoepithelial Kazal-type-associated inhibitor (LEKTI), resulting in unrestricted serine protease activity, increased protein degradation, decomposition and shedding of keratinocytes, and ultimately destruction of the skin's barrier function. Most NS patients present with systemic erythema and scaling at birth or shortly after birth, which gradually transform into annular or creeping erythema and scaling, with a specific bilateral shape at the edge of the lesions, so it is also called tortuous linear ichthyosis. At present, according to reports, 80 different SPINK5 mutations in 144 families have been found to be associated with Netherton syndrome through family gene analysis, including c.81+2T>A, c.153delT, c.2368C>T, etc.

[0003] Currently, the diagnosis of this type of disease is first judged by the rash manifestations, which can easily be misdiagnosed as atopic dermatitis; further observation of hair changes through a dermatoscope to see if there are "bamboo-like" changes; third, a skin pathology examination is performed to confirm the diagnosis, but this diagnosis requires excision of the skin lesions, which can easily leave scars, and the pathological characteristics are non-specific; and because the disease is a hereditary disease, a clear diagnosis currently requires genetic testing.

[0004] Therefore, how to overcome the shortcomings of existing technologies is an urgent problem to be solved in the field of biomedical technology. Summary of the invention

[0005] The purpose of the present invention is to solve the deficiencies of the prior art and provide a kit for detecting Netherton syndrome.

[0006] To achieve the above purpose, the technical solution adopted by the present invention is as follows: A primer pair for detecting Netherton syndrome, characterized in that it comprises a forward primer and a reverse primer; The forward primer is 5'-tggcaagacacatggcaata-3' (SEQ ID NO.1); The reverse primer is 5'-ggacagagtcagcatttcac-3' (SEQ ID NO. 2).

[0007] The invention also provides a kit for detecting Netherton syndrome, which comprises the primer pair and PCR reagent.

[0008] Furthermore, preferably, the PCR reagent is Premix Taq™.

[0009] Furthermore, preferably, the PCR reaction system is Premix Taq™ 13 μL, DNA template 500 ng, forward primer r 10 μM 1 μL, reverse primer 10 μM 1 μL, ddH2O supplemented to 25 μL, and the total volume is 25 μL.

[0010] Furthermore, preferably, the PCR reaction conditions are: pre-denaturation at 98°C for 3 min; 98°C for 10 s, 55°C for 30 s, 72°C for 1 min, 38 cycles; and extension at 72°C for 5 min.

[0011] The present invention provides a kit for detecting Netherton syndrome, which is convenient, fast and specific for detecting through peripheral blood; the kit of the present invention is mainly used to clarify the diagnosis of Netherton syndrome patients, and can also be used to evaluate patients with abnormal skin barrier function. The kit of the present invention is used to detect patients with Netherton syndrome, and if the 2475th base of SPINK5 exon 26 mutates from G to T, it indicates that the patient suffers from Netherton syndrome.

[0012] At present, the applicant has found a patient with NS, collected family blood samples, and screened them through second-generation sequencing. After first-generation sequencing, SPINK5 exon 26 rs2303070 (c.2475G>T) was found, which has not been reported before. Therefore, we will report a new gene locus SPINK5 exon 26 rs2303070 (c.2475G>T) in a patient with Netherton syndrome.

[0013] The present invention has found the SPINK5 exon 26 rs2303070 (c.2475G>T) gene locus, providing a new gene locus for patients with Netherton syndrome and a treatment plan for patients with damaged skin barrier, thereby providing new ideas and plans for the treatment of skin diseases and the development of skin care products.

[0014] The present invention uses peripheral blood from the patient's pedigree for whole exome sequencing (WES). WES showed that the patient's SPINK5 gene had a homozygous mutation, that is, exon 26 was homozygous only in the patient, but heterozygous in the patient's parents, and there was no mutation in the patient's sister or brother. The mutation was confirmed by Sanger sequencing analysis of the patient's family members. Blood samples from the patient's family were collected and sequenced a second time. A single homozygous mutation in SPINK5 (c.2475G>T; p.E825D) was identified in exon 26, which caused Glu at amino acid 825 to become Asp ( Figure 2 ).

[0015] We discovered SPINK5 exon 26 rs2303070 (c.2475G>T) in patients with Netherton syndrome, which provides a new gene locus for the clinical treatment of skin barrier damaged diseases and needs further research and application in the field of skin barrier repair.

[0016] The detection by the kit of the present invention is convenient, rapid and specific. The kit of the present invention can not only be used to clarify the diagnosis of patients with Netherton syndrome, but also can be used to evaluate patients with abnormal skin barrier function, and is easy to promote and apply. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] Figure 1 This is a pedigree chart of patients with Netherton syndrome; Figure 2 Analysis of sequencing results for Netherton syndrome patients and their families. DETAILED DESCRIPTION

[0018] The present invention is further described in detail below in conjunction with embodiments.

[0019] Those skilled in the art will appreciate that the following examples are only used to illustrate the present invention and should not be considered to limit the scope of the present invention. If no specific techniques or conditions are specified in the examples, the techniques or conditions described in the literature in the art or the product specifications are used. If the manufacturer of the materials or equipment used is not specified, they are all conventional products that can be purchased.

[0020] 1. Whole exome sequencing and variant analysis Blood samples were collected from all family members for molecular studies. Genomic DNA was extracted from peripheral blood using a magnetic bead-based universal genomic DNA extraction kit (TIANGEN, catalog number: DP705) using standard procedures (see the instructions for the magnetic bead-based universal genomic DNA extraction kit) and DNA quality was tested.

[0021] First, the genomic DNA was randomly sheared into fragments with an average size of 180-280 bp using Covaris LE220R-plus (Covaris, USA). Secondly, the DNA fragments were end-repaired and A-tailed at the 3' end to obtain a DNA fragment library. DNA fragments with adapters at both ends were selectively amplified and enriched in a PCR reaction (see NEBNext® Ultra™ DNA Library Prep Kit for Illumina instructions). After the PCR reaction, the library was hybridized with a biotin-labeled probe, and then the exons of the gene were captured using streptavidin-containing magnetic beads. The library established by the captured exons was enriched in the PCR reaction in preparation for sequencing. The product was purified using the AMPure XP system (Beckman Coulter, Beverly, USA), and the fragment size of the library was analyzed using the Agilent 5400 system (AATI) (Agilent, USA). The effective concentration (1.5 nM) of the captured exon library was accurately quantified using the qPCR method (Life Technologies, USA) to detect the library quality.

[0022] After the library quality inspection was qualified, high-throughput sequencing was performed using the Illumina NovaSeq 6000 (Illumina, USA) platform using Pair-end 150bp (PE150) according to the effective concentration of the library and the data output. RawData was obtained after the data was downloaded from the machine. RawData was filtered through the following criteria: (1) read pairs with adapters were removed; (2) read pairs with a ratio of N (N indicates that the base information cannot be determined) greater than 10% in single-end sequencing reads were removed; (3) when the number of low-quality (less than 5) bases contained in a single-end sequencing read exceeded 50% of the read length ratio, this pair of reads was removed to obtain CleanData.

[0023] All sequencing data were aligned to the human reference genome (hg19) using the Burrows Wheeler Aligner alignment tool to obtain the initial alignment results in BAM format. Then, Sambamba was used to sort the alignment results and mark duplicate reads. bcftools v1.16 was used to identify SNP and InDel sites, and the internationally used filtering standards (QUAL ≥ 20; DP ≥ 4; MQ ≥ 30) were used to filter SNP and InDel results. In addition, ANNOVAR software was used to annotate the VCF (variant call format) file, that is, the genetic structure of the variant site, the genomic characteristics of the variant site, the impact of non-synonymous mutations on diseases / tumors, including dbSNP and 1000 Genomes SNP databases, and the function of the gene where the mutation is located.

[0024] The mutation detection results are further analyzed and screened for new mutations, harmfulness classification, dominant and recessive pattern screening, etc., so as to obtain mutations that are truly related to the disease being studied.

[0025] We compared the genes of family members and patients and screened out the SPINK5 exon 26rs2303070 (c.2475G>T) gene locus.

[0026] 2. Sanger sequencing To further clarify whether the gene locus is mutated, sequencing was performed on the patient and his family members; Sanger sequencing was performed on the amplified genomic DNA of all family members using polymerase chain reaction (PCR) to verify the presence of the candidate variant.

[0027] SPINK5 primers were designed using Primer3 software, and the primer information is shown in Table 1.

[0028] Table 1 Primer design for SPINK5 gene exons

[0029] Use the Premix Taq™ (Ex Taq™ Version 2.0 plus dye) kit from Beijing Takara Company for detection. Add the reagents listed in Table 2 in sequence into a 200 μL centrifuge tube.

[0030] Table 2 PCR reaction system

[0031] After adding, vortex (2500rpm / min), mix thoroughly, centrifuge briefly and then perform PCR reaction on the machine. The reaction conditions are: 98℃ pre-denaturation for 3min; 98℃ 10 s, 55℃ 30 s, 72℃ 1min, 38 cycles; 72℃ extension for 5min. The specific PCR reaction steps and conditions are shown in Table 3.

[0032] Table 3 PCR reaction steps and specific conditions

[0033] The polymerase chain reaction products were purified with ExoSAP IT (GE Healthcare, Chicago, IL, USA) and sequenced with BigDye Terminator v31 chemistry (Applied Biosystems, Foster City, CA, USA). Sequences were visualized using Sequencer software (Gene Codes, Ann Arbor, MI, USA), and variants were detected by direct inspection of chromatograms. The above sequencing results validated the SPINK5 exon 26 rs2303070 (c.2475G>T) gene locus in the patient. Sanger can be used to detect the SPINK5 exon 26 rs2303070 (c.2475G>T) mutation.

[0034] The patient was a 29-year-old female who was admitted to the hospital because of "erythema, scaling, erosion and itching on the face and trunk for 20 years, and generalized to the whole body for 5 years". Combined with the patient's clinical manifestations and the relevant test results after admission, it was speculated that she had Netherton syndrome. Therefore, blood sampling and whole exome sequencing analysis were performed on the family including the patient and her father, mother, sister, and brother, and the kit of the present invention was used according to the above method to confirm that she had Netherton syndrome. Figure 1 This is the patient's family map, in which the patient has a homozygous mutation, the patient's parents are both heterozygous mutations, and the patient's brother and sister have no mutations. Figure 2 This is the first-generation sequencing result of the patient's family; the results showed that mutation sites were detected in the patient, mutation sites were detected in the patient's parents, and mutation sites were not detected in the patient's younger brothers and sisters.

[0035] The basic principles, main features and advantages of the present invention are shown and described. It should be understood by those skilled in the art that the present invention is not limited by the above embodiments, and the above embodiments and descriptions are only for explaining the principles of the present invention. Without departing from the spirit and scope of the present invention, the present invention may have various changes and improvements, which fall within the scope of the present invention to be protected. The scope of protection of the present invention is defined by the attached claims and their equivalents.

Claims

1. A primer pair for detecting Netherton syndrome, characterized in that: Includes forward primer and reverse primer; The forward primer is 5'-tggcaagacacatggcaata-3' (SEQ ID NO.1); The reverse primer is 5'-ggacagagtcagcatttcac-3' (SEQ ID NO. 2).

2. A kit for detecting Netherton syndrome, characterized in that: The kit comprises the primer pair as claimed in claim 1 and PCR reagents.

3. The kit for treating Netherton syndrome according to claim 2, characterized in that: The PCR reagent is Premix Taq™.

4. The kit for treating Netherton syndrome according to claim 2, characterized in that: The PCR reaction system is Premix Taq™ 13 μL, DNA template 500 ng, forward primer r 10 μM 1 μL, reverse primer 10 μM 1 μL, ddH2O supplemented to 25 μL, total volume 25 μL.

5. The kit for treating Netherton syndrome according to claim 4, characterized in that: The PCR reaction conditions are as follows: pre-denaturation at 98°C for 3 min; 98°C for 10 s, 55°C for 30 s, 72°C for 1 min, 38 cycles; and extension at 72°C for 5 min.